Medications acting on the dopaminergic system in the treatment of alcoholic patients

Current Pharmaceutical Design

Volumn 16, Issue 19, 2010, Pages 2136-2140

  Swift, Robert ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

Alcohol; Dopamine; Nucleus accumbens; Pharmacotherapy; Ventral tegmental area

Indexed keywords

ALCOHOL; ARIPRIPRAZOLE; BACLOFEN; CLOZAPINE; DOPAMINE RECEPTOR STIMULATING AGENT; HALOPERIDOL; NALTREXONE; OLANZAPINE; ONDANSETRON; QUETIAPINE; TIAPRIDE; UNCLASSIFIED DRUG; DOPAMINE; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT;

AGRANULOCYTOSIS; ALCOHOL CONSUMPTION; ALCOHOLISM; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIABETES MELLITUS; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; DRUG EFFICACY; GABAERGIC TRANSMISSION; HUMAN; MOTOR DYSFUNCTION; NEUROBIOLOGY; NEUROLOGIC DISEASE; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; ANIMAL; BEHAVIOR, ADDICTIVE; BRAIN; CONTROLLED CLINICAL TRIAL (TOPIC); DRINKING BEHAVIOR; DRUG EFFECTS; METABOLISM; PATHOPHYSIOLOGY; PREVENTION AND CONTROL;

ALCOHOL DRINKING; ALCOHOLISM; ANIMALS; BEHAVIOR, ADDICTIVE; BRAIN; CONTROLLED CLINICAL TRIALS AS TOPIC; DOPAMINE; DOPAMINE AGENTS; DOPAMINE ANTAGONISTS; HUMANS; RECEPTORS, DOPAMINE;

EID: 77955621453     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210791516323     Document Type: Article

References (72)

1. Koob GF, Volkow ND. Neurocircuitry of Addiction. Neuropsychopharmacol Rev 2009; 1-22.
2. Robinson, TE, Berridge KC. The neural basis of drug craving: An incentive-sensitization theory of addiction. Brain Res Rev 1993; 18: 247-91.
3. Wise RA, Bozarth MA. A psychomotor stimulant theory of addiction. Psychological Rev 1987; 94 (4): 469-92.
4. Koob GF. The neurobiology of addiction: A neuroadaptational view relevant for diagnosis. Addiction 2006; 101(Suppl 1): 23-30.
5. Koob GF. Alcoholism: Allostasis and beyond. Alcoholism: Clinical Exp Res 2006; 27: 232-43.
6. Brodie MS, Shefner SA, Dunwiddie TV. Ethanol increases the firing rate of dopamine neurons of the rat ventral tegmental area in vitro. Brain Res 1990; 508: 65-9.
7. Weiss F, Lorang MT, Bloom FE, et al. Oral alcohol selfadministration stimulates dopamine release in the rat nucleus accumbens: genetic and motivational determinants. J Pharmacol Exp Ther 1993; 267: 250-8.
8. Nestler EJ. Molecular basis of long-term plasticity underlying addiction. Nat Rev Neurosci 2001; 2: 119-28.
9. Ding ZM, Rodd ZA, Engleman EA, et al. Sensitization of ventral tegmental area dopamine neurons to the stimulating effects of ethanol. Alcoholism Clin Exp Res 2009; 33 (9): 1571-81.
10. Ray LA, Hutchison KE. A polymorphism of the mu-opioid receptor gene (OPRM1) and sensitivity to the effects of alcohol in humans. Alcohol Clin Exp Res 2004; 28: 1789-95.
11. Swift RM, Whelihan W, Kuznetsov O, et al. Naltrexone-induced alterations in human ethanol intoxication. Am J Psychiatry 1994; 151: 1463-7.
12. Comings DE, Blum K. Reward deficiency syndrome: genetic aspects of behavioral disorders. Prog Brain Res 2000; 126: 325-41.
13. Bowirrat A, Oscar-Berman M. Relationship between dopaminergic neurotransmission, alcoholism, and Reward Deficiency syndrome. Am J Med Genet B Neuropsychiatr Genet 2005; 5; 132B(1): 29- 37.
14. Diana M, Pistis M, Carboni S, et al. Profound decrement of mesolimbic dopaminergic neuronal activity during ethanol withdrawal syndrome in rats: electrophysiological and biochemical evidence. Proc Natl Acad Sci USA 1993; 90(17): 7966-9.
15. Volkow ND, Fowler JS, Wang GJ, et al. Dopamine in drug abuse and addiction: results of imaging studies and treatment implications. Arch Neurol 2007; 64(11): 1575-9.
16. Mailman RB, Huang X. Dopamine receptor pharmacology. Handbook Clin Neurol 2007; 83: 77-105.
17. Heidbreder C. Selective antagonism at dopamine D3 receptors as a target for drug addiction pharmacotherapy: a review of preclinical evidence. CNS Neurol Disord Drug Targets 2008; 7(5): 410-21.
18. McGeary JG. The DRD4 exon 3 VNTR polymorphism and addiction- related phenotypes: a review. Pharmacol Biochem Behav 2009; 93(3): 222-9.
19. Rayport S. Glutamate is a cotransmitter in ventral midbrain dopamine neurons. Parkinson Relat Disord 2001; 7(3): 261-4.
20. Froehlich JC, Harts J, Lumeng L, et al. Naloxone attenuates voluntary ethanol intake in rats selectively bred for high ethanol preference. Pharmacol Biochem Behav 1990; 35: 385-90.
21. Srisurapanont M, Jarusuraisin N. Naltrexone for the treatment of alcoholism: a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol 2005; 8: 267-80.
22. Benjamin D, Grant E, Pohorecky LA. Naltrexone reverses ethanol induced dopamine release in the nucleus accumbens in awake, freely moving rats. Brain Res 1993; 621: 137-40.
23. Johnson BA, Roache JD, Javors MA, et al. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: A randomized controlled trial. JAMA 2000; 284(8): 963- 71.
24. Colombo G, Vacca G, Serra S, et al. Baclofen suppresses motivation to consume alcohol in rats. Psychopharmacology 2003; 167: 221-4.
25. Colombo G, Addolorato G, Agabio R, et al. Role of GABAB receptor in alcohol dependence: Reducing effect of baclofen on alcohol intake and alcohol motivational properties in rats and amelioration of alcohol withdrawal syndrome and alcohol craving in human alcoholics. Neurotox Res 2004; 6: 403-14.
26. Bettler B, Kaupmann K, Mosbacher J, et al. Molecular structure and physiological functions of GABAB receptors. Physiol Rev 2004; 84: 835-67.
27. Roberto M, Gilpin NW, O'Dell LE, et al. Cellular and behavioral interactions of gabapentin with alcohol dependence. J Neurosci 2008; 28(22): 5762-71.
28. Addolorato G, Caputo F, Capristo E, et al. Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. Alcohol Alcohol 2002; 37(5): 504-8.
29. Addolorato G, Leggio L, Ferrulli A, et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcoholdependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet 2007; 370(9603): 1915-22.
30. Evans SM, Bisaga A. Acute interaction of baclofen in combination with alcohol in heavy social drinkers. Alcohol Clin Exp Res 2009; 33(1): 19-30.
31. Rassnick S, Pulvirenti L, Koob GF. Oral ethanol selfadministration in rats is reduced by the administration of dopamine and glutamate receptor antagonists into the nucleus accumbens. Psychopharmacology 1992; 109: 92-8.
32. Samson HH, Hodge CW, Tolliver GA, et al. Effect of dopamine agonists and antagonists on ethanol-reinforced behavior: the involvement of the nucleus accumbens. Brain Res Bul 1993; 30: 133-41.
33. Price KL, Middaugh LD. The dopamine D1 antagonist reduces ethanol reward for C57BL/6 mice. Alcohol Clin Exp Res 2004; 28: 1666-75.
34. Thanos PK, Katana JM, Ashby CR, Jr. et al. The selective dopamine D3 receptor antagonist SB-277011-A attenuates ethanol consumption in ethanol preferring (P) and non-preferring (NP) rats. Pharmacol Biochem Behav 2005; 81: 190-7.
35. Modell JG, Mountz JM, Glaser FB, et al. Effect of haloperidol on measures of craving and impaired control in alcoholic subjects. Alcohol Clin Exp Res 1993; 17: 234-40.
36. Drake RE, Xie H, McHugo GJ, et al. The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophr Bull 2000; 26: 441-9.
37. Shaw GK, Waller S, Majumdar SK, et al. Tiapride in the prevention of relapse in recently detoxified alcoholics. Brit J Psychiatry 1994; 165: 515-23.
38. Hutchison KE, Swift R, Rohsenow DJ, et al. Olanzapine reduces urge to drink after drinking cues and a priming dose of alcohol. Psychopharmacology 2001; 155: 27-34.
39. Guardia J, Segura L, Gonzalvo B, et al. A double-blind, placebo controlled study of olanzapine in the treatment of alcohol dependence disorder. Alcohol Clin Exp Res 2004; 28(5): 736-45.
40. Hutchison KE, Wooden A, Swift RM, et al. Olanzapine reduces craving for alcohol: a DRD4 VNTR polymorphism by pharmacotherapy interaction. Neuropsychopharmacology 2003; 28: 1882- 8.
41. Hutchison KE, Ray L, Sandman E, et al. The effect of olanzapine on craving and alcohol consumption. Neuropsychopharmacology 2006; 31, 1310-7.
42. Longoria J, Brown ES, Perantie DC, et al. Quetiapine for alcohol use and craving in bipolar disorder. J Clin Psychopharmacol 2004; 24(1): 101-2.
43. Kampman KM, Pettinati HM, Lynch KG, et al. A double-blind, placebo-controlled pilot trial of quetiapine for the treatment of type A and type B alcoholism. J Clin Psychopharmacol 2007; 27(4): 344-51.
44. Babor T, DeHoffman MI, Boca F, et al. Types of alcoholics. I. Evidence for an empirically derived typology based on indicators of vulnerability and severity. Arch Gen Psychiatry 1992; 49: 599- 608.
45. Kosten TR, George TP, Kosten TA. The potential of dopamine agonists in drug addiction. Expert Opin Investig Drugs 2002; 11: 491-9.
46. Xiao C, Shao XM, Olive MF, et al. Ethanol facilitates glutamatergic transmission to dopamine neurons in the ventral tegmental area. Neuropsychopharmacology 2009; 34(2): 307-18.
47. Lawford BR, Young RM, Rowell JA, et al. Bromocriptine in the treatment of alcoholics with the D sub2 dopamine receptor A1 allele. Nat Med 1995; 1(4): 337-41.
48. Naranjo CA, Dongier M, Bremner KE. Long-acting injectable bromocriptine does not reduce relapse in alcoholics. Addiction 1997; 92(8): 969-78.
49. Dackis CA, Kampman KM, Lynch KG, et al. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology 2005; 30(1): 205-11.
50. Shearer J, Darke S, Rodgers C, et al. A double-blind, placebocontrolled trial of modafinil (200 mg/day) for methamphetamine dependence. Addiction 2009; 104(2): 224-33.
51. Saletu B, Saletu M, Grünberger J, et al. Treatment of the alcoholic organic brain syndrome: double-blind, placebo-controlled clinical, psychometric and electroencephalographic mapping studies with modafinil. Neuropsychobiology 1993; 27(1): 26-39.
52. Hoyer D, Boddeke HW. Partial agonists, full agonists, antagonists: dilemmas of definition. Trends Pharmacol Sci 1993; 14: 270-5.
53. Bono G, Balducci C, Richelmi P, et al. Dopamine partial receptor agonists reduce ethanol intake in the rat. Eur J Pharmacol 1996; 296: 233-8.
54. Ingman K, Kupila J, Hyytia P, et al. Effects of aripiprazole on alcohol intake in an animal model of high-alcohol drinking. Alcohol Alcohol 2006; 41: 391-8.
55. Pulvirenti L, Koob GF. Dopamine receptor agonists, partial agonists and psychostimulant addiction. Trends Pharmacol Sci 1994; 15: 374-9.
56. Kranzler HR, Covault J, Pierucci-Lagha A, et al. Effects of aripiprazole on subjective and physiological responses to alcohol. Alcohol Clin Exp Res 2008; 32(4): 573-9.
57. Voronin K, Randall P, Myrick H, et al. Aripiprazole effects on alcohol consumption and subjective reports in a clinical laboratory paradigm--possible influence of self-control. Alcohol Clin Exp Res 2008; 32(11): 1954-61.
58. Myrick H, Anton RF, Li X, et al. The effect of aripiprazole on cueinduced brain activation in alcoholics. Neuropsychopharmacology 2006; 31: S90.
59. Anton RF, Kranzler HR, Breder C, et al. A randomized, multicenter, double-blind, placebo-controlled study of the efficacy and safety of aripiprazole for the treatment of alcohol dependence. J Clin Psychopharmacol 2008; 28: 5-12.
60. Martinotti G, Nicola MD, Janiri L. Efficacy and safety of aripiprazole in alcohol dependence. Am J Drug Alcohol Abuse 2007; 33: 393-401.
61. Kenna GA, Leggio L, Swift RM. A safety and tolerability laboratory study of the combination of aripiprazole and topiramate in volunteers who drink alcohol. Human Neuropsychopharmacol Clin Exp 2009; 24(6): 465-72.
62. Tamion F, Petit J, Massari P, et al. Malignant neuroleptic syndrome during tiapride treatment. J Toxicol Clin Exp 1990; 10: 461-7.
63. Sussman N. The implications of weight changes with antipsychotic treatment. J Clin Psychopharm 2003; 23(3 Suppl 1): S21-6.
64. Osser DN, Najarian DM, Dufresne RL. Olanzapine increases weight and serum triglyceride levels. J Clin Psychiatry 1999; 60: 767-70.
65. Heiskanen T, Niskanen L, Lyytikainen R, et al. Metabolic syndrome in patients with schizophrenia. J Clin Psychiatry 2003; 64: 575-9.
66. Feldman J. Psychopharmacology. Clozapine and agranulocytosis. Psychiatr Serv 1996; 47: 1177-8.
67. Siris SG. Pharmacological treatment of substance-abusing schizophrenia patients. Schizophr Bull 1990; 16: 111-22.
68. McEvoy JP, Freudenreich O, Levin E, et al. Haloperidol increases smoking in patients with schizophrenia. Psychopharmacology 1995; 119: 124-6.
69. Litten RZ, Allen JP. Reducing the desire to drink. pharmacology and neurobiology. Recent Dev Alc 19931; 1: 325-44.
70. Christmas D, Hood S, Nutt D. Potential novel anxiolytic drugs. Curr Pharm Des 2008; 14(33): 3534-46.
71. Mailman RB, Murthy V. Third generation antipsychotic drugs: partial agonism or receptor functional selectivity? Curr Pharm Des 2010; 16(5): 488-501.
72. Wang LL, Yang AK, He SM, et al. Identification of Molecular Targets Associated With Ethanol Toxicity and Implications in Drug Development. Curr Pharm Des 2010; 16(11): 1315-55.